This Research Topic is the second volume of the “Novelties in the Therapeutic Approaches for Chronic Heart Failure: Cardiovascular targets and beyond." Please see the first volume
here.
Despite the progress in the treatment of heart failure, it is a syndrome that is still characterized by high morbidity and mortality, a high socio-economic impact, and whose management is particularly complex. Heart failure therapy can be extremely different in patients with reduced or preserved ejection fraction, in patients with acute decompensated or chronic heart failure, in patients with arrhythmias, or in those with comorbidities. As a consequence, the emerging therapeutic options range from anti-modeling strategies to electrical therapy, management of congestion management, the novel approaches for patients with preserved ejection fraction and comorbidities. The purpose of this special issue is to explore the most innovative therapeutic approaches for chronic heart failure, covering all its complexity.
This Special Issue welcomes original research and review articles about the therapeutic approaches for heart failure under development or under initial clinical evaluation. We encourage to submit both papers focused on cardiovascular drugs or electrical therapy and on the treatment of those comorbidities favoring heart failure worsening.
Submissions are encouraged that discuss new cardiovascular drugs able to revert cardiac remodeling as well as increase inotropism. Articles focused on the congestion, from its monitoring to its management, until diuretic resistance, are also welcome. We encourage the submission of articles about electrical therapy for heart failure. In particular, the novelties in resynchronization therapy and the role of atrial fibrillation and ventricular malignant arrhythmias transcatheter ablation should be explored. Heart transplantation, stem cell therapy, cardiac assistance, unloading approaches for reverse remodeling, and tissue engineering could be also topics of the articles. The novel strategies for the treatment of patients with preserved or mild reduced ejection fraction merit a separate and dedicated discussion. In particular, articles about emerging therapeutic strategies of infiltrative cardiomyopathies, such as amyloidosis, are welcome.
Moreover, we strongly encourage the submission of articles that delve more deeply into the treatment of comorbidities related to heart failure. These articles should discuss the new opportunities coming from SGLT2 inhibitors, in the treatment of endocrine diseases, such as growth hormone deficiency or thyroid deficiency, from the management of cardiorenal syndrome and hyperkalemia. Finally, papers focused on personalized therapeutic strategies based on patients’ monitoring are welcome.
The potential themes include, but are not limited, to the following:
1) Cardiovascular drugs - antiremodelling strategies, new inotropes, and management of congestion and diuretic resistance.
2) Electrical therapy - resyncrhonization therapy and transcatheter ablation of atrial fibrillation and of malignant ventricular arrhythmias.
3) Heart transplantation, stem cell therapy, cardiac assistance, unloading approaches for reverse remodeling, and tissue engineering.
4) Heart failure with mild reduced or preserved ejection fraction - new drugs and therapeutic approaches of infiltrative cardiomyopathies.
5) Other therapeutic approaches including SGLT2 inhibitors, endocrine diseases, cardiorenal syndrome, and management of hyperkalemia and renin-angiotensin-aldosterone inhibition.
6) Remote monitoring and personalized therapeutic approaches.
